Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.

Next Previous
Trial Profile

Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capsaicin (Primary) ; Capsaicin (Primary) ; Amitriptyline
  • Indications Cancer pain; Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms TEC-ORL

Most Recent Events

  • 23 Apr 2025 Status changed from recruiting to active, no longer recruiting.
  • 06 Jul 2023 Planned End Date changed from 1 Aug 2023 to 1 Jan 2026.
  • 06 Jul 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top